Pfizer acquired Chapel Hill, NC-based Bamboo Therapeutics, a gene therapy company. Pfizer previously took ~22% stake for $43M in Q1 2016, then acquired remaining equity for $150M upfront plus up to $495M in milestone payments tied to development, regulatory, and commercial progression (~$645M total). Adds clinical and preclinical AAV gene therapy assets, vector platform, and Phase I/II manufacturing facility (acquired from UNC).
Did it work? Outcome assessment
Strategic verdict
Too Early
Financial impact
Dilutive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 01, 2016
ClosedAug 01, 2016
Deal value$645M
Deal typeAcquisition/Merger
Therapeutic areaRare neuromuscular and CNS diseases